Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jul 12 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-1.20 Insider Own34.48% Shs Outstand25.03M Perf Week16.52%
Market Cap18.18M Forward P/E- EPS next Y-1.17 Insider Trans0.00% Shs Float16.43M Perf Month2.24%
Income-31.92M PEG- EPS next Q-0.29 Inst Own9.73% Short Float1.71% Perf Quarter-33.50%
Sales0.00M P/S- EPS this Y7.20% Inst Trans-0.13% Short Ratio1.18 Perf Half Y-10.52%
Book/sh2.33 P/B0.31 EPS next Y-3.40% ROA-36.55% Short Interest0.28M Perf Year-42.47%
Cash/sh2.32 P/C0.31 EPS next 5Y- ROE-41.63% 52W Range0.51 - 1.94 Perf YTD4.75%
Dividend Est.- P/FCF- EPS past 5Y-16.26% ROI-51.78% 52W High-62.63% Beta0.05
Dividend TTM- Quick Ratio12.07 Sales past 5Y0.00% Gross Margin- 52W Low42.14% ATR (14)0.08
Dividend Ex-Date- Current Ratio12.07 EPS Y/Y TTM20.25% Oper. Margin0.00% RSI (14)50.21 Volatility8.80% 9.10%
Employees27 Debt/Eq0.10 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price4.25
Option/ShortNo / Yes LT Debt/Eq0.05 EPS Q/Q3.25% Payout- Rel Volume0.08 Prev Close0.70
Sales Surprise- EPS Surprise-16.36% Sales Q/Q- EarningsMay 09 BMO Avg Volume238.32K Price0.72
SMA2012.88% SMA50-26.47% SMA200-14.81% Trades Volume19,016 Change3.56%
Date Action Analyst Rating Change Price Target Change
May-14-24Initiated Stephens Overweight $5
Jul-01-21Downgrade Berenberg Buy → Hold $12
Jun-29-21Downgrade Oppenheimer Outperform → Perform $30 → $14
Mar-01-21Initiated Piper Sandler Overweight $25
Mar-01-21Initiated Oppenheimer Outperform $36
Mar-01-21Initiated Citigroup Buy $30
Mar-01-21Initiated Berenberg Buy $27
May-30-24 07:30AM
May-24-24 08:27AM
May-23-24 05:10PM
May-09-24 01:54PM
07:30AM Loading…
Apr-24-24 04:05PM
Apr-09-24 07:30AM
Apr-04-24 04:05PM
Mar-22-24 07:30AM
Mar-06-24 07:30AM
Feb-28-24 07:30AM
Feb-07-24 07:30AM
Jan-04-24 07:30AM
Nov-07-23 08:09AM
07:30AM Loading…
Nov-03-23 04:05PM
Nov-01-23 07:30AM
Oct-25-23 09:05AM
Oct-23-23 07:30AM
Sep-27-23 07:30AM
Sep-21-23 07:30AM
Sep-13-23 07:30AM
Aug-30-23 07:30AM
Aug-19-23 10:44AM
Aug-03-23 07:30AM
Aug-02-23 07:30AM
Jun-13-23 07:30AM
Jun-01-23 07:30AM
May-31-23 07:30AM
07:30AM Loading…
May-09-23 07:30AM
Apr-20-23 07:30AM
Apr-18-23 04:05PM
Apr-13-23 07:30AM
Mar-30-23 07:30AM
Mar-28-23 07:30AM
Mar-23-23 11:56AM
Mar-21-23 07:30AM
Mar-14-23 04:35PM
Mar-07-23 05:15PM
Mar-06-23 07:30AM
Feb-21-23 07:30AM
Feb-16-23 07:30AM
Feb-14-23 07:30AM
Feb-06-23 07:30AM
Jan-05-23 07:30AM
Dec-08-22 01:10PM
Nov-22-22 07:30AM
Nov-21-22 07:30AM
Nov-10-22 09:00AM
Nov-08-22 07:30AM
Nov-07-22 07:30AM
Nov-02-22 07:30AM
Oct-14-22 10:22AM
Oct-05-22 08:05AM
Sep-30-22 04:05PM
Sep-21-22 04:05PM
Aug-31-22 07:30AM
Aug-23-22 07:30AM
Aug-11-22 07:02AM
Aug-09-22 07:30AM
Jun-01-22 07:30AM
May-25-22 07:30AM
May-10-22 07:30AM
May-07-22 09:40AM
Apr-21-22 09:09AM
Mar-10-22 07:30AM
Mar-09-22 04:05PM
Mar-03-22 07:30AM
Feb-11-22 07:30AM
Jan-17-22 11:22AM
Jan-06-22 08:00AM
Dec-16-21 09:01AM
Dec-13-21 04:01PM
Nov-19-21 04:02PM
Nov-17-21 10:37AM
Nov-12-21 07:02AM
Nov-09-21 08:54AM
Nov-03-21 09:01AM
Oct-01-21 08:05AM
Aug-17-21 01:56PM
Aug-09-21 12:00PM
Aug-04-21 07:45AM
Aug-02-21 08:01AM
Jun-29-21 01:49PM
Jun-28-21 04:05PM
May-19-21 05:03PM
May-12-21 07:41AM
May-05-21 08:05AM
May-04-21 07:18AM
Apr-05-21 08:00AM
Mar-25-21 08:00AM
Mar-22-21 08:00AM
Mar-09-21 08:30AM
Mar-05-21 03:30PM
Feb-10-21 04:55PM
Feb-09-21 11:08AM
Sensei Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company which focuses on the discovery, development, and delivery of next generation immunotherapies for the treatment of cancer and infectious diseases. The company was founded in 1999 and is headquartered in Rockville, MD.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Celebi JohnPresident and CEOSep 11 '23Buy0.85500425111,311Sep 13 08:43 AM